The MARITIME HF trial, in patients with HFpEF or HFmrEF and obesity, will investigate mortality, hospitalization, NT-proBNP levels, cardiac function, and quality of life (NCT07037459). The gene discussed is NPPB; the disease is hydrops fetalis.